Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics.
This article represents the proceedings of a symposium, "Development of Novel Pharmacotherapies for the Treatment of Alcohol Dependence: Focus on Antiepileptics," presented at the 2003 annual meeting of the Research Society on Alcoholism in Fort Lauderdale, FL. The organizers and cochairs were Bankole A. Johnson and Robert M. Swift. The presentations were (1) Development of topiramate in the treatment of alcoholism, by Bankole A. Johnson; (2) Craving as a predictor of treatment outcome in pharmacotherapy trials for the treatment of alcoholism, by Nassima Ait-Daoud; (3) Use of biomarkers as a predictor of treatment response in treating alcoholism, by Martin A. Javors; (4) Psychotherapy to enhance compliance with pharmacotherapy in treatment trials for alcohol dependence, by Carlo C. DiClemente; (5) Synopsis of promising medications to treat alcoholism, by Robert M. Swift; and (6) New knowledge on the development of antiepileptic medications for the treatment of alcoholism, by Robert J. Malcolm, Jr.
Johnson
Bankole A
BA
Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, USA. bjohnson@uthscsa.edu
Swift
Robert M
RM
Ait-Daoud
Nassima
N
DiClemente
Carlo C
CC
Javors
Martin A
MA
Malcolm
Robert J
RJ
D000437:Alcoholism / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D011613:Psychotherapy / Q000379:methods; D012955:Societies, Medical; D000077236:Topiramate; D014481:United States
D000927:Anticonvulsants; D015415:Biomarkers; D000077236:Topiramate; D005632:Fructose